Clinical trial

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

NCT03093909

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Gemcitabine Normalized identity: gemcitabineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2017-11-22

PhasePHASE1

Conditions

Malignant Neoplasm of Bone and Articular Cartilageunresolved

Malignant Neoplasms of Female Genital Organsunresolved

Malignant Neoplasms of Independent (Primary) Multiple Sitesunresolved

Malignant Neoplasms of Lip Oral Cavity and Pharynxunresolved

Malignant Neoplasm of Male Genital Organsunresolved

Malignant Neoplasms of Mesothelial and Soft Tissueunresolved

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinomaunresolved

Malignant Neoplasms of Thyroid and Other Endocrine Glandsunresolved

Malignant Neoplasms of Urinary Tractunresolved

Melanoma and Other Malignant Neoplasms of Skinunresolved

Interventions

GemcitabineDRUG · verified · RxNorm: gemcitabine

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

James B. and Lois R. Archer Charitable Foundationcollaborator

Gateway for Cancer Researchcollaborator

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03093909 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.